Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

Teresa Mccarthy Biography and Net Worth

Insider of Avidity Biosciences

Teresa McCarthy, Chief Human Resources Officer, joined Avidity Biosciences in August 2020. Ms. McCarthy is responsible for developing and executing human resource strategies in support of Avidity’s overall business plan and strategic direction. She brings to Avidity decades of experience as an organizational development and human resources consultant in the life science industry. Ms. McCarthy has worked with biotech and healthcare companies at all stages of development via her consulting firm, McCarthy Consultants Inc., and her long-term partnership with The Leadership Edge, Inc. Prior to consulting, Ms. McCarthy held leadership positions at Edwards Lifesciences, Baxter Cardiovascular Group, and IVAC Corporation and received an M.A. degree in Organizational Communication with an emphasis in International Business from San Diego State University.

What is Teresa Mccarthy's net worth?: The estimated net worth of Teresa Mccarthy is at least $3.26 million as of September 23rd, 2024. Ms. Mccarthy owns 69,018 shares of Avidity Biosciences stock worth more than $3,264,551 as of October 5th. This net worth approximation does not reflect any other assets that Ms. Mccarthy may own. Learn More about Teresa Mccarthy's net worth.
How do I contact Teresa Mccarthy?: The corporate mailing address for Ms. Mccarthy and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Teresa Mccarthy's contact information.
Has Teresa Mccarthy been buying or selling shares of Avidity Biosciences?: Teresa Mccarthy has not been actively trading shares of Avidity Biosciences during the last ninety days. Most recently, Teresa Mccarthy sold 13,153 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $44.00, for a transaction totalling $578,732.00. Following the completion of the sale, the insider now directly owns 69,018 shares of the company's stock, valued at $3,036,792. Learn More on Teresa Mccarthy's trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), and Teresa Mccarthy (Insider). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 26 times. They sold a total of 795,358 shares worth more than $25,998,643.75. The most recent insider tranaction occured on September, 23rd when insider Teresa Mccarthy sold 13,153 shares worth more than $578,732.00. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 9/23/2024.

Teresa Mccarthy Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/23/2024	Sell	13,153	$44.00	$578,732.00	69,018

Teresa Mccarthy Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $47.30

$47.08

$48.61

50 Day Range

MA: $43.75

$40.46

$48.51

2 Week Range

Now: $47.30

$4.82

$49.41

Volume

766,320 shs

Average Volume

1,373,027 shs

Market Capitalization

$4.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89